Annual report pursuant to Section 13 and 15(d)

16. QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details)

v3.19.1
16. QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
REVENUES:            
Product revenue $ 4,020,715 $ 4,194,602 $ 4,620,841 $ 4,006,298 $ 16,842,456 $ 15,617,726
License and other revenue 35,709 35,708 35,709 35,708 0 7,000,000
Total Revenues 4,056,424 4,230,310 4,656,550 4,042,006 16,985,290 22,760,560
OPERATING EXPENSES:            
Cost of product revenue (exclusive of amortization expense shown below) 11,142,116 9,164,109 9,645,662 12,242,748 42,194,635 29,164,321
Research and development 917,304 1,002,818 [1] 1,040,427 [1] 965,571 [1] 3,926,120 5,570,029
Plasma center operating expenses 2,260,379 1,973,338 1,738,128 1,833,774 7,805,619 6,503,750
Amortization of intangibles 211,234 211,235 211,234 211,235 844,938 1,234,674
Selling, general and administrative 6,073,051 5,670,210 [1] 5,438,480 [1] 5,321,181 [1] 22,502,922 18,752,393
Total operating expenses 20,604,084 18,021,710 18,073,931 20,574,509 77,274,234 62,070,556
LOSS FROM OPERATIONS (16,547,660) (13,791,400) (13,417,381) (16,532,503) (60,288,944) (39,309,996)
OTHER INCOME (EXPENSE):            
Interest income 60,206 75,581 33,070 26,546 195,403 57,228
Interest expense (1,437,968) (1,402,475) (1,359,188) (1,323,152) (5,522,783) (3,285,847)
Other expense (112,565) (17,191) (4,332) 6,967 (127,121) (10,144)
Other expense, net (1,490,327) (1,344,085) (1,330,450) (1,289,639) (5,454,501) (4,448,979)
NET LOSS $ (18,037,987) $ (15,135,485) $ (14,747,831) $ (17,822,142) $ (65,743,445) $ (43,758,975)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.39) $ (0.33) $ (0.35) $ (0.39) $ (1.45) $ (1.91)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted 46,351,860 46,350,392 42,712,168 45,317,042 45,188,899 22,896,042
[1] For the three months ended March 31, June 30, and September 30, 2018, the Company reclassified $0.3 million, $0.4 million and $0.3 million, respectively, of operating expenses from Research and development expenses to Selling, general and administrative expenses.